FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
9 letters match. Newest first.
-
DrugsVedic Lifesciences Pvt. Ltd.
FDA warns Vedic Lifesciences over false final reports for three nonclinical drug studies.
Medium -
DevicesPalamur Biosciences Private Limited
FDA warns Palamur Biosciences over GLP violations in medical device safety testing and inadequate corrective actions.
High risk -
DevicesJiangsu Kerbio Medical Technology Group Co.
FDA cites Jiangsu Kerbio Medical Technology Group for serious GLP violations in medical device safety testing.
High risk -
DevicesCCIC Huatongwei International Inspection Co., Ltd.
FDA warns CCIC Huatongwei after inspection found copied data and missing records in medical device safety tests.
High risk -
DevicesMid-Link Testing Company, Ltd
FDA warns Mid-Link Testing over unreliable Good Laboratory Practice (GLP) safety data for medical device tests.
High risk -
DevicesSanitation & Environmental Technology Institute dba SDWH
FDA found GLP violations in SDWH's nonclinical testing of medical devices, raising doubts about safety data.
High risk -
DrugsSamm Solutions, Inc., d.b.a. BTS Research
Samm Solutions/BTS Research failed good laboratory practice (GLP) rules for nonclinical drug studies, FDA says.
Medium -
BiologicsValley Biosystems
FDA cited Valley Biosystems, a California biologics testing lab, for Good Laboratory Practice violations that call its nonclinical study data into question.
High risk -
BiologicsToxikon Corporation/Labcorp Bedford LLC
FDA warned Toxikon/Labcorp Bedford over GLP violations in a biologics nonclinical study, including incorrect kidney-function calculations and failed QA review.
Medium